Serine/Threonine Protein Kinase Pim 2 (Pim 2h or Proto Oncogene Pim 2 or PIM2 or EC 2.7.11.1) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Pages: 44 Published: February 28, 2022 Report Code: GMDGDHC22021TDB

The serine/threonine protein kinase pim 2 (Pim 2h or Proto Oncogene Pim 2 or PIM2 or EC 2.7.11.1) targeted pipeline therapeutics report provides comprehensive information on the serine/threonine protein kinase pim 2 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in serine/threonine protein kinase pim 2 targeted therapeutics development with respective active and dormant or discontinued projects.

What are the key indications in the serine/threonine protein kinase pim 2 targeted pipeline market?

Some of the key indications in the serine/threonine protein kinase pim 2 targeted pipeline market are hematological tumor, acute myelocytic leukemia (AML, acute myeloblastic leukemia), myelofibrosis, acute lymphocytic leukemia (ALL, acute lymphoblastic leukemia), bladder cancer, breast cancer, chronic lymphocytic leukemia (CLL), colon cancer, diffuse large B-cell lymphoma, and liver cancer.

Serine/threonine protein kinase pim 2 targeted pipeline market, by indications

Serine/threonine protein kinase pim 2 targeted pipeline market, by indications

For more indication insights, download a free sample

Which are the key companies in the serine/threonine protein kinase pim 2 targeted pipeline market?

The key companies in the serine/threonine protein kinase pim 2 targeted pipeline market are Amgen Inc, Incyte Corp, Inflection Biosciences Ltd, NewBay Medical Technology Co Ltd, Novartis AG, Sanofi, Sumitomo Dainippon Pharma Oncology, Inc, Yakult Honsha Co Ltd, and Zovis Pharmaceuticals.

Amgen Inc

Amgen Inc (Amgen) is a biotechnology company which discovers, develops, manufactures and markets innovative human therapeutics to treat patients suffering from serious diseases. It develops novel medicines in six focused therapeutic areas including cardiovascular disease, oncology/hematology, inflammation, bone health, neuroscience and nephrology. The company develops products by using advanced human genetics to unravel the difficulties of disease and understand the fundamentals of human biology.

Incyte Corp

Incyte Corp (Incyte) is a biopharmaceutical company, which discovers, develops and commercializes proprietary cancer therapeutics. The company’s lead product, Jakafi (ruxolitinib) is marketed in the US for the treatment of patients with high-risk myelofibrosis; and polycythemia vera who are intolerant to hydroxyurea. The company distributes Jakafi through a network of specialty pharmacy providers and wholesalers. In collaboration with Incyte, Novartis International Pharmaceutical Ltd (Novartis) develops and commercializes ruxolitinib outside the US for hematologic and cancer indications under the name Jakavi.

Inflection Biosciences Ltd

Inflection Biosciences Ltd (Inflection Biosciences) is a drug development company focused on the discovery and development of small molecule therapeutics for the treatment of cancer. The company’s pipeline products include dual mechanism kinase inhibitors and pim kinase inhibitors including IBL-300, IBL-202 and IBL-100.

Serine/threonine protein kinase pim 2 targeted pipeline market, by key companies

Serine/threonine protein kinase pim 2 targeted pipeline market, by key companies

To know more about key companies, download a free sample

Market overview

Key indications Hematological Tumor, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Myelofibrosis, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Bladder Cancer, Breast Cancer, Chronic Lymphocytic Leukemia (CLL), Colon Cancer, Diffuse Large B-Cell Lymphoma, and Liver Cancer
Key companies Amgen Inc, Incyte Corp, Inflection Biosciences Ltd, NewBay Medical Technology Co Ltd, Novartis AG, Sanofi, Sumitomo Dainippon Pharma Oncology, Inc, Yakult Honsha Co Ltd, and Zovis Pharmaceuticals

Scope

  • The report provides a snapshot of the global therapeutic landscape for Serine/Threonine Protein Kinase Pim 2 (Pim 2h or Proto Oncogene Pim 2 or PIM2 or EC 2.7.11.1)
  • The report reviews Serine/Threonine Protein Kinase Pim 2 (Pim 2h or Proto Oncogene Pim 2 or PIM2 or EC 2.7.11.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Serine/Threonine Protein Kinase Pim 2 (Pim 2h or Proto Oncogene Pim 2 or PIM2 or EC 2.7.11.1) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Serine/Threonine Protein Kinase Pim 2 (Pim 2h or Proto Oncogene Pim 2 or PIM2 or EC 2.7.11.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Serine/Threonine Protein Kinase Pim 2 (Pim 2h or Proto Oncogene Pim 2 or PIM2 or EC 2.7.11.1) targeted therapeutics

Reasons to Buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Serine/Threonine Protein Kinase Pim 2 (Pim 2h or Proto Oncogene Pim 2 or PIM2 or EC 2.7.11.1) Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Serine/Threonine Protein Kinase Pim 2 (Pim 2h or Proto Oncogene Pim 2 or PIM2 or EC 2.7.11.1) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope”

Key Players

  • Amgen Inc

    Incyte Corp

    Inflection Biosciences Ltd

    NewBay Medical Technology Co Ltd

    Novartis AG

    Sanofi

    Sumitomo Dainippon Pharma Oncology

  • Inc

    Yakult Honsha Co Ltd

    Zovis Pharmaceuticals

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Serine/Threonine Protein Kinase Pim 2 (Pim 2h or Proto Oncogene Pim 2 or PIM2 or EC

2.7.11.1) – Overview

Serine/Threonine Protein Kinase Pim 2 (Pim 2h or Proto Oncogene Pim 2 or PIM2 or EC

2.7.11.1) – Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Serine/Threonine Protein Kinase Pim 2 (Pim 2h or Proto Oncogene Pim 2 or PIM2 or EC

2.7.11.1) – Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Serine/Threonine Protein Kinase Pim 2 (Pim 2h or Proto Oncogene Pim 2 or PIM2 or EC

2.7.11.1) – Companies Involved in Therapeutics Development

Amgen Inc

Incyte Corp

Inflection Biosciences Ltd

NewBay Medical Technology Co Ltd

Novartis AG

Sanofi

Sumitomo Dainippon Pharma Oncology, Inc

Yakult Honsha Co Ltd

Zovis Pharmaceuticals

Serine/Threonine Protein Kinase Pim 2 (Pim 2h or Proto Oncogene Pim 2 or PIM2 or EC

2.7.11.1) – Drug Profiles

GDC-0570 – Drug Profile

Product Description

Mechanism Of Action

History of Events

IBL-100 – Drug Profile

Product Description

Mechanism Of Action

History of Events

INCB-53914 – Drug Profile

Product Description

Mechanism Of Action

History of Events

JP-11646 – Drug Profile

Product Description

Mechanism Of Action

History of Events

LGB-321 – Drug Profile

Product Description

Mechanism Of Action

Small Molecule to Inhibit PIM1 and PIM2 for Hematological Tumors – Drug Profile

Product Description

Mechanism Of Action

History of Events

Small Molecule to Inhibit PIM1, PIM2 and PIM3 for Solid Tumors and Hematological Tumors – Drug Profile

Product Description

Mechanism Of Action

History of Events

Small Molecules to Inhibit PIM1 and PIM2 for Oncology – Drug Profile

Product Description

Mechanism Of Action

Small Molecules to Inhibit PIM2 for Oncology – Drug Profile

Product Description

Mechanism Of Action

TP-3654 – Drug Profile

Product Description

Mechanism Of Action

History of Events

Serine/Threonine Protein Kinase Pim 2 (Pim 2h or Proto Oncogene Pim 2 or PIM2 or EC

2.7.11.1) – Dormant Products

Serine/Threonine Protein Kinase Pim 2 (Pim 2h or Proto Oncogene Pim 2 or PIM2 or EC

2.7.11.1) – Discontinued Products

Serine/Threonine Protein Kinase Pim 2 (Pim 2h or Proto Oncogene Pim 2 or PIM2 or EC

2.7.11.1) – Product Development Milestones

Featured News & Press Releases

Apr 10, 2021: Sumitomo Dainippon Pharma Oncology presents on TP-3654 at AACR Virtual Annual Meeting I 2021

May 29, 2020: Tolero Pharmaceuticals presents findings from first clinical studies evaluating investigational agent TP-3654 in patients with advanced solid tumors at ASCO Virtual Annual Meeting 2020

Apr 06, 2020: Boston Biomedical announces first patient dosed in phase 1 study of investigational agent TP-3654 in patients with myelofibrosis

May 14, 2019: Tolero Pharmaceuticals announces first patient dosed in phase 1 study of investigational agent TP-3654 in patients with advanced solid tumors

Oct 23, 2017: Tolero Pharma To Present Preclinical Data Supporting Development of Cancer Drug Candidate TP-3654 for Myc-dependent Triple Negative Breast Cancer

Oct 05, 2017: Tolero Pharma to Deliver Keynote Presentations at 9th International Conference on Leukemia and Hematologic Oncology

Jun 30, 2014: Tolero’s PIM Kinase Inhibitor Demonstrates Promising Activity in Preclinical Models of Urothelial Carcinoma

Apr 04, 2014: Roswell Park to Present Findings on Jasco Pharmaceuticals’ Novel PIM Inhibitor at AACR 2014

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development by Stage of Development, 2022

Number of Products under Development by Therapy Areas, 2022

Number of Products under Development by Indications, 2022

Number of Products under Development by Indications, 2022 (Contd..1)

Number of Products under Development by Companies, 2022

Products under Development by Companies, 2022

Products under Development by Companies, 2022 (Contd..1)

Number of Products by Stage and Mechanism of Actions, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Pipeline by Amgen Inc, 2022

Pipeline by Incyte Corp, 2022

Pipeline by Inflection Biosciences Ltd, 2022

Pipeline by NewBay Medical Technology Co Ltd, 2022

Pipeline by Novartis AG, 2022

Pipeline by Sanofi, 2022

Pipeline by Sumitomo Dainippon Pharma Oncology, Inc, 2022

Pipeline by Yakult Honsha Co Ltd, 2022

Pipeline by Zovis Pharmaceuticals, 2022

Dormant Products, 2022

Dormant Products, 2022 (Contd..1)

Discontinued Products, 2022

List of Figures

List of Figures

Number of Products under Development by Stage of Development, 2022

Number of Products under Development by Top 10 Indications, 2022

Number of Products by Stage and Mechanism of Actions, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Frequently Asked Questions

$3500

Can be used by individual purchaser only

$10500

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 (0) 20 7947 2960

GDPR + CCPA Compliant

Personal and transaction information are kept safe from unauthorised use.

Recently Viewed Reports

Looking to stay on top of industry & market trends?

Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.